A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 976
- 试验地点
- 1
- 主要终点
- Progression-free survival of patients in both study groups
研究概览
简要总结
This is a study of the efficacy and safety of Caelyx (pegylated liposomal doxorubicin) in combination with carboplatin compared to the standard treatment of paclitaxel and carboplatin in patients with epithelial ovarian cancer in late relapse (> 6 months).
详细描述
The main purpose of this research study is to find out if treatment of late relapse of ovarian or fallopian tube or primary peritoneal cancer with liposomal doxorubicin (Caelyx) combined with carboplatin will control the tumor growth at least as well as standard treatment of paclitaxel and carboplatin. And it is hoped that substituting paclitaxel with Caelyx in combination with carboplatin will improve the tolerance of the treatment program with at least the same efficacy and fewer side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients aged > 18
- •Histologically proven diagnosis of cancer of the ovary, the fallopian tube or extra-ovarian papillary serous tumors
- •Measurable disease (Response Evaluation Criteria in Solid Tumor [RECIST] criteria) or cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup [GCIG] criteria) or with histologically proven diagnosis of relapse
- •Disease in progression > 6 months after a first or second platinum-based line. Patients should have previously received a taxane derivative.
- •ECOG performance status < 2
- •Life expectancy of at least 12 weeks
- •Adequate bone marrow, renal, and hepatic function
排除标准
- •Ovarian tumors of low malignant potential
- •Non-epithelial ovarian or mixed epithelial/non-epithelial tumors
- •Previous radiotherapy
- •Prior diagnosis of malignancy
- •Bowel obstruction, sub-occlusive disease, or presence of symptomatic brain metastases
- •Pre-existing motor or sensory neurologic pathology or symptoms National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade > 1
- •History of congestive heart failure (New York Heart Association [NYHA] classification > 2), history of myocardial infarction within the last 6 months, or history of atrial or ventricular arrhythmias
- •Severe active infection
- •Severe hypersensitivity to products containing Cremophor EL and/or to compounds chemically related to paclitaxel, carboplatin or Caelyx
- •Fertile women not using adequate contraceptive methods
- •Pregnant or breast feeding women
研究组 & 干预措施
Standard
Paclitaxel-Carboplatin
干预措施: Carboplatin (Drug)
Standard
Paclitaxel-Carboplatin
干预措施: Paclitaxel (Drug)
Experimental
Caelyx-Carboplatin
干预措施: Pegylated liposomal doxorubicin (Drug)
Experimental
Caelyx-Carboplatin
干预措施: Carboplatin (Drug)
结局指标
主要结局
Progression-free survival of patients in both study groups
时间窗: 5 years
次要结局
- Qualitative and quantitative toxicities(6 months)
- Quality of life(6 months)
- Overall survival(5 years)